PhoreMost utilizes its proprietary SITESEEKER® technology to identify and target previously undruggable proteins, focusing on novel therapeutic candidates in oncology and Targeted Protein Degradation (TPD). The company collaborates with industry partners to develop effective treatments for challenging diseases, enhancing the druggable space in the pharmaceutical landscape.
Funding
$12M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many disease-causing proteins are considered "undruggable" because they lack traditional binding sites for small-molecule drugs, limiting therapeutic options for a range of diseases, especially in oncology. Conventional drug discovery methods struggle to identify novel ways to modulate the activity of these challenging protein targets.
Solution
PhoreMost utilizes its SITESEEKER® technology, a proprietary protein interference platform, to identify and validate novel druggable sites on previously inaccessible proteins. This approach enables the development of new therapeutic modalities, including small molecules and targeted protein degraders (TPDs), against these challenging targets. By expanding the druggable proteome, PhoreMost aims to create effective treatments for diseases with limited or no existing therapeutic options, particularly in oncology and inflammation.
Target Audience
PhoreMost's primary customers are pharmaceutical and biotechnology companies seeking innovative approaches to drug discovery, particularly for challenging protein targets in oncology, inflammation, and other disease areas.
Features
- SITESEEKER® platform for systematic screening of protein-protein interaction sites
- Identification of cryptic binding pockets on traditionally "undruggable" proteins
- Generation of novel peptide-based inhibitors and molecular glues
- Development of targeted protein degradation (TPD) therapeutics
- Focus on oncology and inflammation targets with high unmet medical need
- Collaborative drug discovery partnerships to accelerate therapeutic development